Brief: Caris Life Sciences Receives Moldx Approval For Caris Chromoseq, Advancing Access To Comprehensive Genomic Profiling For Myeloid Malignancies
04/05/2026 13:33
May 4 (Reuters) - Caris Life Sciences Inc CAI.O: CARIS LIFE SCIENCES RECEIVES MOLDX APPROVAL FOR CARIS CHROMOSEQ, ADVANCING ACCESS TO COMPREHENSIVE GENOMIC PROFILING FOR MYELOID MALIGNANCIES Source text: ID:nPnbGYD4Wa Further company coverage: CAI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Caris Life Sciences
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Caris Life Sciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Caris Life Sciences Q2 revenue rises 45% on the back of molecular profiling services
Caris Life Sciences Inc expected to post earnings of 1 cent a share - Earnings Preview
Caris Life Sciences Q1 revenue rises on demand for molecular profiling services